CC-5013 and Rituximab in Waldenstrom's Macroglobulinemia

This study has been completed.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Celgene Corporation
Genentech, Inc.
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00142168
First received: September 1, 2005
Last updated: June 23, 2011
Last verified: June 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2008
  Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)